- Open
- 68.50
- High
- 71.00
- Low
- 67.30
- Close
- 68.80
- Change
- -0.50 (-0.73%)
- Volume
- 1,344,743
⌘K
| 5 Jun 2026 | 07:00:02 | Oversubscribed Strategic Equity Fundraise of £9m |
| 1 Jun 2026 | 15:00:00 | Block Listing - Application to AIM |
| 1 Jun 2026 | 07:00:09 | Clinical data on AVA6000 in salivary gland cancers |
| 29 May 2026 | 07:00:05 | Posting of Annual Report and Notice of AGM |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 6 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 10 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
Avacta Group is a company that is creating innovative cancer treatments and advanced diagnostic tools using its two exclusive technologies - Affimer® biologics and pre|CISION™ targeted chemotherapy for tumors.
| 5 Jun 2026 | 07:00:02 | Oversubscribed Strategic Equity Fundraise of £9m |
| 1 Jun 2026 | 15:00:00 | Block Listing - Application to AIM |
| 1 Jun 2026 | 07:00:09 | Clinical data on AVA6000 in salivary gland cancers |
| 29 May 2026 | 07:00:05 | Posting of Annual Report and Notice of AGM |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 6 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 10 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
Avacta Group is a company that is creating innovative cancer treatments and advanced diagnostic tools using its two exclusive technologies - Affimer® biologics and pre|CISION™ targeted chemotherapy for tumors.
| 29 May 2026 | 07:00:04 | Board Director Changes |
Lord Fink and Lord Stevens of Ludgate have interests in this issuer
| 29 May 2026 | 07:00:04 | Board Director Changes |
Lord Fink and Lord Stevens of Ludgate have interests in this issuer